Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. The Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.

Zymeworks Inc.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Nurix Therapeutics (NRIX), Taysha Gene Therapies (TS...

Analysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NRIX), Taysha Gene Therapies (TSHA) and Zymeworks (ZYME)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BioCryst (BCRX) and Zymeworks (ZYME) with bullish se...

Analysts Are Bullish on Top Healthcare Stocks: BioCryst (BCRX), Zymeworks (ZYME)

Zymeworks ( ($ZYME) ) has issued an update. On June 28, 2026, Zymeworks Inc. agreed to acquire Theravance Biopharma, Inc. through a merger in which...

Zymeworks to Acquire Theravance in Strategic Merger

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Zymeworks (ZYME), Maze Therapeutics, Inc. (MAZE) and...

Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Maze Therapeutics, Inc. (MAZE) and Universal Health (UHS)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Zymeworks (ZYME), Amylyx Pharmaceuticals Inc (AMLX) ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ZYME	$24.94	-3.63%	340.71K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ZYME	$24.94	-3.6%	340.71K
3
4
5
6

ZYME

ZYME

Get Zymeworks Inc. Data in Excel

Get Zymeworks Inc. Data in Excel